Josephine van Dongen

7 Evaluation of implementing a targeted rotavirus vaccine program 173 Acknowledgements: All RIVAR study team members*, survey and interview respondents and (parents of) participants are gratefully acknowledged for their contribution to this study. *RIVAR study team, rivar@umcutrecht.nl: Zwar t L.M., Julius Center for Health Science and Primary Care, University Medical Center Utrecht, Utrecht, the Netherlands;Tims-Polderman C., Julius Center for Health Science and Primary Care, University Medical Center Utrecht, Utrecht, the Netherlands; Beurden, van M., Julius Center for Health Science and Primary Care, University Medical Center Utrecht, Utrecht, the Netherlands; Bont, L.J., Depar tment of Pediatrics, University Medical Center Utrecht, Utrecht, the Netherlands; Norbruis O.F., Depar tment of Pediatrics, Isala Hospital, Zwolle, the Netherlands; Hemels, M.A.C., Depar tment of Pediatrics, Isala Hospital, Zwolle, the Netherlands;Well, van G.T.J., Depar tment of Pediatrics, Maastricht University Medical Center,Maastricht, the Netherlands;Vlieger,A.M., Depar tment of Pediatrics, St.Antonius Hospital, Nieuwegein, the Netherlands; Sluijs, van der J., Depar tment of Pediatrics, Maxima Medical Centre, Veldhoven, the Netherlands; Stas, H.G., Depar tment of Pediatrics, Maasstad Hospital, Rotterdam, the Netherlands; Tramper-Stranders, G., Depar tment of Pediatrics, St. Franciscus Hospital, Rotterdam, the Netherlands; Kleinlugtenbeld, E.A., Depar tment of Pediatrics, Alber t Schweitzer Hospital, Rotterdam, the Netherlands; Kempen, van A.A.M.W., Depar tment of Pediatrics, Onze LieveVrouwe Gasthuis,Amsterdam, the Netherlands;Wessels, M., Depar tment of Pediatrics, Rijnstate Hospital, Arnhem, the Netherlands; Rossem, van M.C., Depar tment of Pediatrics, Rijnstate Hospital, Arnhem, the Netherlands; Dassel, A.C.M., Depar tment of Pediatrics, Deventer Hospital, Deventer, the Netherlands; Houten, van M.A., Depar tment of Pediatrics, Spaarne Gasthuis, Hoofddorp and Haarlem, the Netherlands; Pajkr t, D. , Depar tment of Pediatrics, Amsterdam University Medical Center, Amsterdam, the Netherlands. Ethical Approval and Consent to participate: The RIVAR study protocol was approved by the Institutional Review Board of University Medical Center Utrecht, which declared it does not involve the Human Subject Act. Funding: This work was suppor ted by the Netherlands Organization for Health Research and Development (grant number 836021024), Healthcare Insurers Innovation Foundation, GlaxoSmithKline Biologicals SA (study ID 203108) and UMC Utrecht. GlaxoSmithKline Biologicals SA was provided the oppor tunity to review a preliminary version of this manuscript for factual accuracy, but the authors are solely responsible for final content and interpretation. No sponsor had a role in design, collection, analysis, writing or decision to submit the article. This study is registered as NTR5361 in the Dutch trial registry (www.trialregister.nl ).